FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate
FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate Uses, Dosage, Side Effects, Food Interaction and all others data.
FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute. It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01).
| Trade Name | FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate |
| Generic | FINLAY-FR-1 |
| FINLAY-FR-1 Other Names | FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate, Soberana 01 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here FINLAY-FR-1 Anti-SARS-CoV-2 Vaccine Candidate
